Plasma Free Amino Acids in Patients With Hepatic Encephalopathy and Its Impact on Disease Outcomes.
试验速览
- 阶段
- 不适用
- 入组人数
- 100
- 主要终点
- Amino acid profile in hepatic encephalopathy
研究概览
简要总结
This is study to investigate the plasma free amino acids profile in patients with decompensated liver cirrhosis and hepatic encephalopathy and its relation to the nutritional state of these patients.
- To investigate the plasma free amino acids relation to the nutritional state of patients with liver cirrhosis and hepatic encephalopathy.
- To determine the effectiveness, cost, cost-benefit and in-hospital prognosis of branched chain amino acid (BCAA) infusion as an adjuvant to conventional mainstay therapy in the treatment of hepatic encephalopathy due to liver cirrhosis.
- To determine the effectiveness of branched chain amino acid (BCAA) infusion on improving amino acid imbalance and Fischer ratio (Branched chain amino acids/Aromatic amino acids ratio).
详细描述
Alterations in amino acid profiles observed in patients with liver cirrhosis are very specific and markedly differ from those observed in other disorders..
Until present time the treatment of hepatic encephalopathy is mainly aimed at reducing the production and intestinal absorption of ammonia by antibiotics and non-absorbable disaccharides, although the available data indicate a low success rate of these strategies.
Beneficial effects of branched chain amino acids supplementation (BCAA) may be more pronounced in patients with marked depression of BCAA and/or low Branched chain amino acids/Aromatic amino acids (BCAA/AAA) ratio in extracellular fluid.
It also may be suggested that the beneficial effect of long term intake of BCAA on hepatic encephalopathy demonstrated in clinical studies is related to improved muscle mass and nutritional status.
The current recommendation only includes oral BCAA to patients with liver disease who are intolerant to standard protein intake.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patient has decompensated liver cirrhosis
- •Patient has overt hepatic encephalopathy
排除标准
- •Protein losing enteropathy.
- •Neurological conditions that make the assessment of hepatic encephalopathy difficult
- •Parkinson's disease
- •Alzheimer's disease
- •Concomitant stroke
- •Gastrointestinal Bleeding requiring blood transfusion
研究组 & 干预措施
hepatic encephalopathy patients-amino
The following will be administered to this group of patients rifaximin 550 tablets b.i.d Lactulose syrup 5cm b.i.d Enema b.i.d plus Aminoleban (8% amino acids infusion) b.i.d for 3 days
干预措施: Aminoleban (8% amino acids infusion) (Drug)
结局指标
主要结局
Amino acid profile in hepatic encephalopathy
时间窗: 24 hours
Measuring the level of plasma different free amino acids in hepatic encephalopathy patients
次要结局
- Relation between amino acids and nutrition(24 hours)
- IV Amino acids infusion effect(up to 1 week)
研究者
Mahmoud Hamed Goda
Specialist
Assiut University